Mirena and other levonorgestrel intrauterine systems can have a treatment role in endometrial hyperplasia, but the pathology matters. Hyperplasia without atypia differs from EIN or atypical hyperplasia, which can coexist with cancer. Fertility-sparing treatment requires careful selection and surveillance, not simply insertion of a device.
A device widely known for contraception can also deliver progestin directly to the endometrium. Its treatment role depends on the pathological diagnosis and the person’s goals.
Different diagnoses carry different risks
Hyperplasia without atypia differs from EIN or atypical hyperplasia. EIN–AEH can coexist with cancer, making careful assessment essential before fertility-sparing treatment.
Progestin counteracts endometrial proliferation; treatment is not simply a matter of making the lining shed naturally.
- Delivery: Intrauterine progestin acts locally but does not eliminate systemic or procedure-related adverse effects.
- Response: Regression rates depend on pathology, regimen and follow-up; no single percentage applies to everyone.
- Follow-up: Response must be checked, especially when atypia or EIN is present.
Local delivery with ongoing assessment
A levonorgestrel intrauterine system is one option, but it still has adverse effects and insertion-related risks. Suitability requires clinical assessment.
If a fertility-sparing approach is chosen, documented response and a pregnancy plan must be coordinated with the treating team. Regression does not guarantee future conception or eliminate recurrence risk.
Clinical Considerations
While the Mirena IUS is highly effective, it is not a “one-size-fits-all” solution. It may not be suitable for patients with severe uterine cavity distortion or large submucosal fibroids that interfere with device placement. Furthermore, patients with AEH or early-stage endometrial cancer must undergo regular endometrial biopsies to monitor the lesion’s progression or regression throughout the treatment process.
Preserve options with appropriate safeguards
Intrauterine progestin may be a useful fertility-sparing option for selected patients. It is not universally superior, and the pathology and follow-up plan remain central.
Disclaimer: This report is for informational purposes. Clinical decisions regarding endometrial hyperplasia must be made in consultation with a board-certified gynecologist, considering the patient’s specific anatomical and reproductive status.
Atypia changes the safety discussion
For EIN–AEH, hysterectomy is definitive treatment. If fertility-sparing treatment is considered, concurrent cancer should be excluded as far as possible and response monitored. ACOG recommends repeat histological assessment within 3–6 months of initial progestin treatment. ACOG Clinical Consensus No. 5 (2023).